Last reviewed · How we verify
BIIB023 - low dose IV Dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BIIB023 - low dose IV Dose (BIIB023 - low dose IV Dose) — Biogen.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BIIB023 - low dose IV Dose TARGET | BIIB023 - low dose IV Dose | Biogen | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BIIB023 - low dose IV Dose CI watch — RSS
- BIIB023 - low dose IV Dose CI watch — Atom
- BIIB023 - low dose IV Dose CI watch — JSON
- BIIB023 - low dose IV Dose alone — RSS
Cite this brief
Drug Landscape (2026). BIIB023 - low dose IV Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/biib023-low-dose-iv-dose. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab